期刊文献+

曲美他嗪治疗糖尿病并发冠心病心力衰竭临床疗效观察 被引量:8

暂未订购
导出
摘要 目的观察曲美他嗪治疗2型糖尿病伴冠心病心力衰竭临床疗效。方法将48例2型糖尿病合并冠心病心力衰竭患者随机分成常规口服药物组(对照组)24例和曲美他嗪组(治疗组)24例,治疗组在常规口服药物治疗的基础上加用曲美他嗪20mg口服,每日3次。治疗6个月,观察两组患者于治疗前后空腹血糖(FBG)、餐后2h血糖(2hFBG)及心脏B超测量左室射血分数(LVEF)、左室舒张末期容积(LVEDD)、左室收缩末期容积(LVESD)、左室等容舒张时间(IVRT)等指标。结果治疗组患者左室射血分数(LVEF)、左室舒张末期容积(LVEDD)、左室等容舒张时间(IVRT)、左室收缩末期容积(LVESD)均较治疗前有明显改善(P<0.05)。结论2型糖尿病合并冠心病心力衰竭患者在常规药物治疗基础上加用曲美他嗪,可以通过优化2型糖尿病患者的心肌能量代谢,明显提高心肌收缩和舒张功能,从而改善患者的心功能。
作者 梁德坚
出处 《国际医药卫生导报》 2009年第19期60-61,共2页 International Medicine and Health Guidance News
  • 相关文献

参考文献5

二级参考文献25

  • 1Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart, 1997,78:353.
  • 2Detry JM, Leclercq PJ. Trimetazidine European Multicenter study versus propranold in stable angina pectoris: contribution of Holter electrocardiographic ambulatory mornitoring. Am J Cardio, 1995,76:8B.
  • 3Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the joint International and Federation of Cardiology/World Health Organization task force on Standarizasion of clinical nomendature. Circulation,1979,59:607.
  • 4Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Presses Med, 1998,27:2100.
  • 5Fantimi E, DemaisonL, SentexE, etal. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol,1994,26:949.
  • 6Kay L. Improvement of long- term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function. Am J Cardiol, 1995,76:45b.
  • 7Mody FV, Singh BN, Mohiuddin IH, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluaion by positron emission tomography. Am J Cardiol. 1998,82(5A) :42K ~ 49K.
  • 8Cahalin LP, Mathier MA, Semigran MJ, at al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure[J] .Chest. 1996,110(2) :325 - 331.
  • 9Peeters P, Mets T.The 6-minute walk as an appropriate exercise test in elderly patents with chronic heart failure[J] .J Gerontol A Biol Sci Med Sci. 1996,51(4) :M147 - M151.
  • 10Ferrari R.Metabolic treatment of myocardial ischaemia. Eur Heart J.1999,20:1144 - 1145.

共引文献57

同被引文献49

  • 1王东明,陈宋明,李玉华,王伟.曲美他嗪治疗缺血性心脏病心力衰竭[J].中国医师进修杂志(内科版),2006,29(1):47-48. 被引量:40
  • 2胡爱英,张泽萍,仲罕婷.影响慢性心力衰竭患者再入院的因素分析[J].中华护理杂志,2006,41(4):373-375. 被引量:73
  • 3梁叶青,邓大宏,严健渝.曲美他嗪改善老年缺血性心肌病患者左室功能疗效观察[J].中国医师进修杂志,2006,29(1):59-59. 被引量:9
  • 4李莉,孙俐俐.运动训练与心力衰竭[J].心血管康复医学杂志,2006,15(4):414-416. 被引量:9
  • 5邹晓霞 但三利.曲美他嗪对糖尿病心肌病患者的保护效应[J].中国基层医药,2009,16:2-2.
  • 6Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic sub- jects with and without prior myocardial infarction. N Engl J Med, 1998,339(4) :229-234.
  • 7Kantor PF, Lueien A, Kozak R, et al. The antianginaldrug trimeta- zidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-keto- acyl coenzymeA thiolase. Cite Res ,2000,86 (5) : 580-588.
  • 8Marziu IM. Cardioprotective effects trimetazidine: a review [ J]. Curt" Med Res Opin,2003,19(7) :661 -672.
  • 9Fen'ari R, Cicchitell IG, N[erl IE, et al. Metabolic modulation and opti- mization of energy consumption in heart failure[J]. Med Clin North Am,2003,87 ( 2 ) :493 - 507.
  • 10陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部